Celecoxib, but not rofecoxib or naproxen, attenuates cardiac hypertrophy and fibrosis induced in vitro by angiotensin and aldosterone

Clinical and Experimental Pharmacology and Physiology

Volumn 37, Issue 9, 2010, Pages 912-918

  Wang, Bing H ^a   Bertuci, Micka ^a   Ma, Jian Yang ^a   Adrahtas, Anastasia ^a   Cheung, Raymond Y ^b   Krum, Henry ^a  

^a MONASH UNIVERSITY   (Australia)

^b PFIZER INC   (United States)

Author keywords

aldosterone; angiotensin II; cardiac fibrosis; cardiac hypertrophy; celecoxib; cyclo oxygenase 2 inhibitors; noproxen; rofecoxib

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; CELECOXIB; COLLAGEN; LEUCINE; NAPROXEN; PROLINE; ROFECOXIB;

ANIMAL CELL; ARTICLE; CELL STRAIN HEPG2; CENTRIFUGATION; COLLAGEN SYNTHESIS; CONTROLLED STUDY; CRYOPRESERVATION; DRUG EFFECT; DRUG SELECTIVITY; ENZYME IMMUNOASSAY; FEMALE; FIBROBLAST; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; NEWBORN; NONHUMAN; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPRAGUE DAWLEY RAT;

ALDOSTERONE; ANGIOTENSIN II; ANIMALS; ANIMALS, NEWBORN; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOMEGALY; COLLAGEN; CYCLOOXYGENASE 2 INHIBITORS; FEMALE; FIBROBLASTS; FIBROSIS; HEART; HEP G2 CELLS; HEPATOCYTES; HUMANS; LACTONES; MALE; MYOCARDIUM; MYOCYTES, CARDIAC; NAPROXEN; PYRAZOLES; RATS; RENIN-ANGIOTENSIN SYSTEM; SULFONAMIDES; SULFONES; VASOCONSTRICTOR AGENTS;

EID: 77956030148     PISSN: 03051870     EISSN: 14401681     Source Type: Journal    
DOI: 10.1111/j.1440-1681.2010.05405.x     Document Type: Article

References (28)

1. Gislason GH, Rasmussen JN, Abildstrom SZ et al. Increased mortality and cardiovascular morbidity associated with use of nonsteroidal anti-inflammatory drugs in chronic heart failure. Arch. Intern. Med. 2009 169 : 141 149.
2. Krotz F, Schiele TM, Klauss V, Sohn HY. Selective COX-2 inhibitors and risk of myocardial infarction. J. Vasc. Res. 2005 42 : 312 324.
3. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 1998 38 : 97 120.
4. Zidar N, Dolenc-Strazar Z, Jeruc J et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the normal human heart and in myocardial infarction. Cardiovasc. Pathol. 2007 16 : 300 304.
5. LaPointe MC, Mendez M, Leung A, Tao Z, Yang XP. Inhibition of cyclooxygenase-2 improves cardiac function after myocardial infarction in the mouse. Am. J. Physiol. Heart Circ. Physiol. 2004 286 : H1416 24.
6. Saito T, Rodger IW, Hu F, Robinson R, Huynh T, Giaid A. Inhibition of COX pathway in experimental myocardial infarction. J. Mol. Cell. Cardiol. 2004 37 : 71 7.
7. Timmers L, Sluijter JP, Verlaan CW et al. Cyclooxygenase-2 inhibition increases mortality, enhances left ventricular remodeling, and impairs systolic function after myocardial infarction in the pig. Circulation 2007 115 : 326 332.
8. Jugdutt BI. Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction. Circulation 2007 115 : 288 291.
9. 2 synthase-1 deletion leads to adverse left ventricular remodeling after myocardial infarction. Circulation 2008 117 : 1701 1710.
10. Halpin RA, Porras AG, Geer LA et al. The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects. Drug Metab. Dispos. 2002 30 : 684 693.
11. Delyani JA. Anti-aldosterone therapy in the treatment of heart failure: New thoughts on an old hormone. Expert Opin. Investig. Drugs 1998 7 : 753 759.
12. Dieterich HA, Wendt C, Saborowski F. Cardioprotection by aldosterone receptor antagonism in heart failure. Part I. The role of aldosterone in heart failure. Fiziol. Cheloveka 2005 31 : 97 105 (in Russian).
13. Lim S. Blockade of renin-angiotensin-aldosterone system in kidney and heart disease: How much do we need? Acta Med. Indones. 2008 40 : 34 7.
14. Knights KM, Mangoni AA, Miners JO. Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: Is aldosterone the silent partner in crime? Br. J. Clin. Pharmacol. 2006 61 : 738 740.
15. Latif SA, Conca TJ, Morris DJ. The effects of the licorice derivative, glycyrrhetinic acid, on hepatic 3 alpha- and 3 beta-hydroxysteroid dehydrogenases and 5 alpha- and 5 beta-reductase pathways of metabolism of aldosterone in male rats. Steroids 1990 55 : 52 8.
16. Okoshi MP, Yan X, Okoshi K et al. Aldosterone directly stimulates cardiac myocyte hypertrophy. J. Card. Fail. 2004 10 : 511 518.
17. Simpson P. Stimulation of hypertrophy of cultured neonatal rat heart cells through an alpha 1-adrenergic receptor and induction of beating through an alpha 1- and beta 1-adrenergic receptor interaction. Evidence for independent regulation of growth and beating. Circ. Res. 1985 56 : 884 894.
18. Woodcock EA, Wang BH, Arthur JF et al. Inositol polyphosphate 1-phosphatase is a novel antihypertrophic factor. J. Biol. Chem. 2002 277 : 22734 22742.
19. Phrommintikul A, Tran L, Kompa A et al. Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction. Am. J. Physiol. Heart Circ. Physiol. 2008 294 : H1804 14.
20. Mosmann T. Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J. Immunol. Methods 1983 65 : 55 63.
21. Supino R. MTT assays. Methods Mol. Biol. 1995 43 : 137 149.
22. Patti R, Gumired K, Reddanna P, Sutton LN, Phillips PC, Reddy CD. Overexpression of cyclooxygenase-2 (COX-2) in human primitive neuroectodermal tumors: Effect of celecoxib and rofecoxib. Cancer Lett. 2002 180 : 13 21.
23. Zhang Z, Lai GH, Sirica AE. Celecoxib-induced apoptosis in rat cholangiocarcinoma cells mediated by Akt inactivation and Bax translocation. Hepatology 2004 39 : 1028 1037.
24. Yang HM, Kim HS, Park KW et al. Celecoxib, a cyclooxygenase-2 inhibitor, reduces neointimal hyperplasia through inhibition of Akt signaling. Circulation 2004 110 : 301 308.
25. Koo BK, Kim YS, Park KW et al. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): An open-label randomised controlled study. Lancet 2007 370 : 567 574.
26. Chung JW, Kwon DA, Suh JW et al. Two-year clinical follow-up of COREA-TAXUS trial: Long-term safety and efficacy of celecoxib for 6 months after paclitaxel-eluting stents implantation. Circulation 2008 118 : S747 (Abstract).
27. Jacobshagen C, Gruber M, Teucher N et al. Celecoxib modulates hypertrophic signalling and prevents load-induced cardiac dysfunction. Eur. J. Heart Fail. 2008 10 : 334 342.
28. Dorn GW 2nd., Force T. Protein kinase cascades in the regulation of cardiac hypertrophy. J. Clin. Invest. 2005 115 : 527 537.